Trifluridine/tipiracil
Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
... to trifluridine/ tipiracil plus bevacizumab or irinotecan, fluoropyrimidine and bevacizumab and stratified according to RAS status (wild type vs ...with trifluridine/tipiracil plus bevacizumab ...
5
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
... the trifluridine/tipiracil compassionate use program in The Netherlands were invited to participate in the ...of trifluridine/tipiracil cycles, toxicities, number of dose delays and dose ...
8
Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
... Abstract: Patients with metastatic colorectal cancer (mCRC) are surviving longer now than ever before, but mortality rates are still high and more effective therapies are clearly needed. For patients with disease that is ...
9
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
... The duration of the three health states was derived as described below; a schematic is shown in figure 1. TOX was defined as time spent with grade 3 or 4 treat- ment-related AEs after randomisation and before disease ...
6
<p>Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study</p>
... including chemotherapy with or without radiation therapy, depending on regional guidelines and tumor stage. 2–5 For metastatic CRC (mCRC), the backbone of the current fi rst- line standard of care is 5- fl uorouracil ...
13
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
... Patients and methods We retrospectively analysed the data of consecutive mCRC patients treated with REG or FTD/TPI and classified them into slow- growing or rapid- growing (SG or RG)[r] ...
7
Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
... Abstract: TAS-102, with its robust survival efficacy and feasible toxicity, is one of the standard salvage-line treatments for patients with metastatic colorectal cancer (mCRC).. No de[r] ...
7
<p>Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date</p>
... and tipiracil, a thymidine phosphorylase inhibitor, in a ...uridine/ tipiracil, and later a global Phase III trial (TAGS trial) that compared tri fl uridine/tipiracil vs placebo with best supportive ...
7
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
... The current analysis seems to confirm a trend between the good ECOG PS and response to TAS-102 (p=0.08), supporting the concept that patients with mCRC in good clinical conditions, ev[r] ...
6
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
... Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorec[r] ...
10
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
... include trifluridine/tipiracil (TAS-102) and ...either trifluridine/tipiracil or regorafenib may be appropriate as both can extend patient ...of trifluridine/tipiracil and ...
8
Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.
... In this work, we have demonstrated the effectiveness of an optimised 18 F-trifluoromethylation procedure to radiolabel a nucleoside substrate. Furthermore, we successfully adapted the procedure for automation, to provide ...
15
PRODUCT MONOGRAPH. Trifluridine Ophthalmic Solution, 1% Topical Antiviral Agent St-Elzear Blvd. West September 29, 2020 Laval, Quebec H7L 4A8
... Administration of trifluridine to the dog at 6.0 mg/kg/day resulted in body weight loss, reduced appetite, emesis, soft or watery feces, decreased total leukocyte counts, thrombocytopenia, a mild normocytic ...
21
METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF TRIFLURIDINE AND TIPIRACIL IN TABLET DOSAGE FORM BY RP-HPLC METHOD
... A simple, specific, accurate and precise reverse phase HPLC method has been developed and validated for the simultaneous estimation of Trifluridine (FTD) and Tipiracil (TPI) in Tablet dosage form. ...
8
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR STIMULTANEOUS ESTIMATION OF TRIFLURIDINE AND TIPIRACIL BY RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM
... of trifluridine (FTD) Figure.1 and tipiracil (TPI) Figure ...cancer. Trifluridine is Nucleoside Analog Antiviral a fluorinated thymidine analog with potential antineoplastic ...activity. ...
5
RP HPLC method development and validation for simultaneous determination of trifluridine and tipiracil in pure and tablet dosage form
... of Trifluridine and Tipiracil in pure tablet dosage form and bulk drug, different parameters were tried to elute both drugs with good resolution, less tailing factor and greater plate ...for ...
10